CLASS II ONGOING Drug recall · Reported 5 Nov 2025 · FDA Enforcement Report

Prazosin Hydrochloride, Capsules, USP, 5 mg recalled

Amerisource Health Services is recalling Prazosin Hydrochloride, Capsules, USP, 5 mg, distributed nationwide in the US. The recall was initiated on 16 Oct 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: 1016996, 1018336, 1021220, Exp. Date 11/30/2025; 1022421, 1025017, Exp. Date 08/31/2026.
NDC60687-572
Quantity recalled3,410 cartons

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0103-2026
FDA event ID
97826
Recalling firm
Amerisource Health Services, Columbus, OH
Manufacturer
American Health Packaging
Classification
Class II
Status
Ongoing
Recall initiated
16 Oct 2025
FDA classified
24 Oct 2025
Reported
5 Nov 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity

Timeline

16 Oct 2025Recall initiated by company
24 Oct 2025Classified by FDA+8 days
5 Nov 2025Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Prazosin Hydrochloride, Capsules, USP, 5 mg, 20 capsules (5x4) cartons, Rx only, Distributed by American Health Packaging, Columbus, Ohio 43217, carton NDC 60687-572-32, Individual unit dose: NDC 60687-572-33

Where it was distributed

Nationwide within the United States

Nationwide

Questions about this recall

Why was it recalled?

Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit

Which lots are affected?

Lot #: 1016996, 1018336, 1021220, Exp. Date 11/30/2025; 1022421, 1025017, Exp. Date 08/31/2026.

Where was it sold?

Nationwide within the United States

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

2 other products · FDA event 97826
ReportedClassRecallCompanyReasonWhere
CLASS IIPrazosin Hydrochloride, Capsules, USP, 2 mg recalledPrazosin HydrochlorideAmerisource Health ServicesNitrosamine ImpurityNationwide
CLASS IIPrazosin Hydrochloride, Capsules, USP, 1 mg recalledPrazosin HydrochlorideAmerisource Health ServicesNitrosamine ImpurityNationwide

More recalls from Amerisource Health Services

All 69

Other Prazosin recalls

All 10